Development of a novel pretargeting system with bifunctional nucleic acid molecules

Biochemical and Biophysical Research Communications

Volumn 386, Issue 3, 2009, Pages 521-525

  Zhou, Jing ^a   Soontornworajit, Boonchoy ^a   Snipes, Matthew P ^a   Wang, Yong ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Antibody; Aptamer; Cancer cell; Drug delivery; Pretargeting

Indexed keywords

APTAMER; CELL RECEPTOR; DNA; NUCLEIC ACID; PROTEIN TYROSINE KINASE; RNA; TRANSFERRIN RECEPTOR;

ALGORITHM; ARTICLE; CANCER CELL; CELL LABELING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PRETARGETING; DRUG TARGETING; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERNALIZATION; LEUKEMIA CELL; LIGAND BINDING; MOLECULE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PRIORITY JOURNAL; RECEPTOR BINDING; TARGET CELL;

APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; DNA; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 67650034249     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.06.090     Document Type: Article

References (29)

1. Goldenberg D.M., DeLand F.H., Bennett S.J., Primus F.J., Nelson M.O., Flanigan R.C., McRoberts J.W., Bruce A.W., and Mahan D.E. Radioimmunodetection of prostatic cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging. JAMA 250 (1983) 630-635
2. Goodwin D.A., and Meares C.F. Advances in pretargeting biotechnology. Biotechnol. Adv. 19 (2001) 435-450
3. Sharkey R.M., Karacay H., Cardillo T.M., Chang C.H., McBride W.J., Rossi E.A., Horak I.D., and Goldenberg D.M. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin. Cancer Res. 11 (2005) 7109s-7121s
4. Reardan D.T., Meares C.F., Goodwin D.A., McTigue M., David G.S., Stone M.R., Leung J.P., Bartholomew R.M., and Frincke J.M. Antibodies against metal chelates. Nature 316 (1985) 265-268
5. Yuan F., Baxter L.T., and Jain R.K. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res. 51 (1991) 3119-3130
6. Baxter L.T., Zhu H., Mackensen D.G., and Jain R.K. Physiologically-based pharmacokinetic model for specific and nonspecific monoclonal-antibodies and fragments in normal-tissues and human tumor xenografts in nude-mice. Cancer Res. 54 (1994) 1517-1528
7. Ellington A.D., and Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 346 (1990) 818-822
8. Tuerk C., and Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 (1990) 505-510
9. Nimjee S.M., Rusconi C.P., and Sullenger B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56 (2005) 555-583
10. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., Claesson-Welsh L., and Janjic N. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273 (1998) 20556-20567
11. Chu T.C., Marks III J.W., Lavery L.A., Faulkner S., Rosenblum M.G., Ellington A.D., and Levy M. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 66 (2006) 5989-5992
12. McNamara II J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., Sullenger B.A., and Giangrande P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24 (2006) 1005-1015
13. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., Richie J.P., and Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 103 (2006) 6315-6320
14. Yuan B.F., Zhuang X.Y., Hao Y.H., and Tan Z. Kinetics of base stacking-aided DNA hybridization. Chem. Commun. 48 (2008) 6600-6602
15. Mathews D.H., Disney M.D., Childs J.L., Schroeder S.J., Zuker M., and Turner D.H. Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc. Natl. Acad. Sci. USA 101 (2004) 7287-7292
16. Shangguan D., Cao Z., Meng L., Mallikaratchy P., Sefah K., Wang H., Li Y., and Tan W. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. 7 (2008) 2133-2139
17. Shangguan D., Li Y., Tang Z., Cao Z.C., Chen H.W., Mallikaratchy P., Sefah K., Yang C.J., and Tan W. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. USA 103 (2006) 11838-11843
18. Shangguan D., Tang Z., Mallikaratchy P., Xiao Z., and Tan W. Optimization and modifications of aptamers selected from live cancer cell lines. Chembiochem 8 (2007) 603-606
19. Schuster P. Prediction of RNA secondary structures: from theory to models and real molecules. Rep. Prog. Phys. 69 (2006) 1419-1477
20. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31 (2003) 3406-3415
21. Jossinet F., Ludwig T.E., and Westhof E. RNA structure: bioinformatic analysis. Curr. Opin. Microbiol. 10 (2007) 279-285
22. Chen S.J. RNA folding: conformational statistics, folding kinetics, and ion electrostatics. Annu. Rev. Biophys. 37 (2008) 197-214
23. Williamson J.R. Induced fit in RNA-protein recognition. Nat. Struct. Biol. 7 (2000) 834-837
24. Daniels T.R., Delgado T., Rodriguez J.A., Helguera G., and Penichet M.L. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121 (2006) 144-158
25. Stiles C.D. The molecular biology of platelet-derived growth factor. Cell 33 (1983) 653-655
26. Wikstrand C.J., Cokgor I., Sampson J.H., and Bigner D.D. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev. 18 (1999) 451-464
27. Liu G., Dou S., Yin D., Squires S., Liu X., Wang Y., Rusckowski M., and Hnatowich D.J. A novel pretargeting method for measuring antibody internalization in tumor cells. Cancer Biother. Radiopharm. 22 (2007) 33-39
28. Xiao Z., Shangguan D., Cao Z., Fang X., and Tan W. Cell-specific internalization study of an aptamer from whole cell selection. Chemistry 14 (2008) 1769-1775
29. Huang Y.F., Shangguan D., Liu H., Phillips J.A., Zhang X., Chen Y., and Tan W. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 10 (2009) 862-868